Gossamer Bio Q2 Operational Loss $(26.1)M; Going Concern Warning, 46% Workforce Cut
Gossamer Bio reported a Q2 2026 operational loss of $(26.1) million, an improvement from the prior year, but achieved a net income of $16.9 million primarily due to a significant gain on debt extinguishment. The company issued a going concern warning, indicating insufficient cash to fund operations for at least one year, and implemented a 46% workforce reduction in Q1 2026. Cash and cash equivalents saw a slight increase, but total current assets declined significantly, while shares outstanding more than doubled due to a convertible notes exchange.
Key Highlights
- Workforce reduction of 46% (73 individuals) initiated in Q1 2026 to reduce operating expenses.
- Issued a going concern warning, citing insufficient cash to fund operations for at least one year.
- Reported an operational loss of $(26.1) million for Q2 2026, an improvement from $(38.8) million in Q2 2025.
- Achieved net income of $16.9 million in Q2 2026, primarily due to a $43.8 million gain on debt extinguishment.
- Cash and cash equivalents increased to $41.1 million as of June 30, 2026, from $37.7 million at year-end 2025.
- Total current assets decreased to $72.7 million from $167.6 million as of December 31, 2025.
- Shares outstanding significantly increased to 488.8 million from 233.7 million due to debt exchange.
- Accumulated deficit grew to $(1,468.7) million as of June 30, 2026.
Price Impact
More from GOSS
Gossamer Bio Reacquires Seralutinib Rights, Cuts Debt by $115.9M; Q2 Net Income $16.9M
Gossamer Bio Reacquires Seralutinib Rights, Plans Sep 2026 FDA NDA
Gossamer Bio Boosts Authorized Shares to 4B; Approves Reverse Split